论文部分内容阅读
Background Clopidogrel requires bioactivation in vivo to convert the pro-drug into its active metabolite to show its antiplatelet effects.The variability in the clinical response to clopidogrel treatment has been attributed to genetic factors,but specific genes and mechanisms underlying clopidogrel bioactivation remain unclear.